The largest program at SMRI is for the identification of medications that will improve the treatment of schizophrenia and bipolar disorder. Although medications have been available since the 1960s, they have proven to be only partially effective. Many individuals affected with these diseases continue to have symptoms even when taking available medications, while others find it difficult to take medications because of side effects.
The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. At any given time, SMRI is supporting 50-60 treatment trials, the majority of which are generic and/or off-label medications.
The deadline for the 2018 application cycle has now passed. Details regarding any future calls for proposals will be posted on the website when they are available.
Do you have an ongoing trial with SMRI? Please submit your quarterly report here. Please note that quarterly reports are due January 15, April 15, July 15 and October 15 each year.